Regulatory GSK again pulls application for leucovorin, touted by FDA as potential autism treatment BioSpaceGSK discontinued Wellcovorin in 1999, but the FDA in September last year asked the pharma to refile an application, pointing to its potential to...RegulatoryNeuroscienceRead full story pharminent April 10, 2026 (Last updated: April 10, 2026) BioSpace GSK discontinued Wellcovorin in 1999, but the FDA in September last year asked the pharma to refile an application, pointing to its potential to… RegulatoryNeuroscienceRead full story Post navigation Previous: Roche places a $1bn bet on C4T degrader-antibody conjugatesNext: Senju launches first-in-class dry eye disease drug in Japan Related Stories Regulatory Scholar Rock’s muscle-targeting SMA therapy Isemblyd lands FDA approval pharminent September 14, 2026 Regulatory Psychedelic therapies ride wave of public favor into FDA hearing pharminent September 14, 2026 Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026